Stereotaxis, Inc. (NYSEAMERICAN:STXS - Get Free Report) shares traded down 2.2% during trading on Thursday . The company traded as low as $2.18 and last traded at $2.19. 271,151 shares were traded during mid-day trading, a decline of 12% from the average session volume of 306,758 shares. The stock had previously closed at $2.24.
Stereotaxis Stock Up 6.8 %
The stock has a market cap of $198.27 million, a P/E ratio of -8.36 and a beta of 1.57.
Stereotaxis (NYSEAMERICAN:STXS - Get Free Report) last released its earnings results on Monday, November 11th. The company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.03). The company had revenue of $9.20 million during the quarter, compared to analysts' expectations of $6.80 million. Stereotaxis had a negative return on equity of 162.54% and a negative net margin of 85.79%. Analysts forecast that Stereotaxis, Inc. will post -0.26 EPS for the current fiscal year.
Hedge Funds Weigh In On Stereotaxis
A number of institutional investors and hedge funds have recently made changes to their positions in the business. SG Americas Securities LLC purchased a new position in shares of Stereotaxis in the 3rd quarter worth approximately $39,000. Forum Financial Management LP purchased a new position in Stereotaxis during the second quarter worth $48,000. Jane Street Group LLC boosted its stake in Stereotaxis by 26.9% during the third quarter. Jane Street Group LLC now owns 29,773 shares of the company's stock worth $61,000 after buying an additional 6,313 shares during the period. Rhumbline Advisers increased its position in Stereotaxis by 645.6% during the second quarter. Rhumbline Advisers now owns 48,251 shares of the company's stock valued at $88,000 after acquiring an additional 41,780 shares during the last quarter. Finally, Barclays PLC raised its stake in shares of Stereotaxis by 449.9% in the third quarter. Barclays PLC now owns 101,953 shares of the company's stock valued at $208,000 after acquiring an additional 83,412 shares during the period. 45.35% of the stock is owned by hedge funds and other institutional investors.
About Stereotaxis
(
Get Free Report)
Stereotaxis, Inc designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites.
Recommended Stories
Before you consider Stereotaxis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stereotaxis wasn't on the list.
While Stereotaxis currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
